title: ACUTE RETINAL NECROSIS AFTER ADMINISTRATION OF ADALIMUMAB, A SYSTEMIC ANTITUMOR NECROSIS FACTOR ANTIBODY.
abstract: OBJECTIVE
  To report a case of acute retinal necrosis in a patient on anti-tumor necrosis factor α immunosuppressive therapy.
  
  
  METHODS
  Case report.
  
  
  RESULTS
  A 47-year-old man with psoriasis presented with blurred vision and floaters in the left eye 4 days after receiving his fourth dose of adalimumab, a tumor necrosis factor α antagonist. He was diagnosed with acute retinal necrosis and was treated with intravenous acyclovir as well as prophylactic laser barricade. Seven years later, he is 20/20 with no history of a retinal detachment.
  
  
  CONCLUSIONS
  Physicians prescribing tumor necrosis factor α antagonist immunosuppressive therapy should be aware of the potential of developing acute retinal necrosis.
authors.affiliation: Department of Ophthalmology and Visual Sciences, University of Maryland, Baltimore, Maryland.
authors.forename: Sid A
authors.initials: SA
authors.lastname: Schechet
authors.affiliation: Department of Medicine, University of Maryland Midtown Campus, Baltimore, Maryland.
authors.forename: Kevin
authors.initials: K
authors.lastname: Garff
authors.affiliation: Department of Ophthalmology and Visual Sciences, University of Maryland, Baltimore, Maryland.
authors.forename: Karen
authors.initials: K
authors.lastname: Klima
authors.affiliation: Department of Medicine, Medstar Union Memorial Hospital, Baltimore, Maryland.
authors.forename: Wayne
authors.initials: W
authors.lastname: Campbell
authors.affiliation: Department of Ophthalmology and Visual Sciences, University of Maryland, Baltimore, Maryland.
authors.forename: Lisa S
authors.initials: LS
authors.lastname: Schocket
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015882:Retinal Necrosis Syndrome, Acute / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab